Biogen (BIIB) PT Lowered to $296 at Baird as Aduhelm Numbers Seen Weak on Safety Issues
Tweet Send to a Friend
Baird analyst Brian Skorney lowered the price target on Biogen (NASDAQ: BIIB) to $296.00 (from $382.00) while maintaining a Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
